ELEV

Elevation Oncology
ELEV

Overview Fund Activity
Delisted

ELEV was delisted on the 22nd of July, 2025.

Back to rankings

36 hedge funds and large institutions have $217M invested in Elevation Oncology in 2021 Q2 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

Holders
36
Holders Change
+36
Holders Change %
–
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
%
% of All Funds
0.03%
New
36
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACM
1
Aisling Capital Management
New York
$38.5M
2
VP
2
venBio Partners
California
$35.4M
3
DCM
3
Driehaus Capital Management
Illinois
$26.5M
4
CAM
4
Cormorant Asset Management
Massachusetts
$25.6M
5
BI
5
BVF Inc
California
$21.6M

Top Sellers

No sellers this quarter
Name Market Value Shares Shares
Change 		Shares
Change %
SSA
26
Schonfeld Strategic Advisors
New York
$349K 25,700 +25,700 New
Qube Research & Technologies (QRT)
27
Qube Research & Technologies (QRT)
United Kingdom
$329K 24,255 +24,255 New
WMSA
28
Weiss Multi-Strategy Advisers
New York
$204K 15,037 +15,037 New
MS
29
Maven Securities
Jersey
$204K 16,000 +16,000 New
PHK
30
Point72 Hong Kong
Hong Kong
$131K 9,649 +9,649 New
Northern Trust
31
Northern Trust
Illinois
$65K 4,803 +4,803 New
WCMNY
32
Westchester Capital Management (New York)
New York
$14K 1,000 +1,000 New
UBS Group
33
UBS Group
Switzerland
$14K 1,045 +1,045 New
OCM
34
Ovata Capital Management
Hong Kong
$7K 500 +500 New
SPIA
35
Steward Partners Investment Advisory
New York
$7K 500 +500 New
CSS
36
Cubist Systematic Strategies
Connecticut
$1K 100 +100 New
CFGS
37
Concourse Financial Group Securities
Alabama
– – – –
1
2